The company could finally be ready to deliver on years of promise.
MarketBeat on MSN
CRISPR Therapeutics gains after earnings as pipeline hope grows
CRISPR Therapeutics AG (NASDAQ: CRSP) stock is up more than 12% after the gene editing pioneer reported its Q4 2025 earnings ...
CRISPR Therapeutics (NASDAQ:CRSP) executives highlighted progress across its oncology and autoimmune cell therapy pipeline ...
CRISPR Therapeutics' CASGEVY gene-editing therapy targets severe SCD and TDT. Click here to read why CRSP stock is rated as a Buy.
Antibiotic resistance is racing toward a global crisis, with “superbugs” projected to cause over 10 million deaths annually by 2050. Now, scientists at UC San Diego have unveiled a powerful new CRISPR ...
Durham, North Carolina and Oxford, United Kingdom, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Pairwise, a global innovator in agriculture, today ...
A sales partner offered a ray of hope that this company couldn't for itself.
A version of this Priestley Medal address will be presented at the American Chemical Society Spring 2026 meeting ...
If you are wondering whether CRISPR Therapeutics at around US$53.52 is offering good value today, you are not alone. The stock often attracts investors who care about price versus potential. The share ...
CRISPR Therapeutics AG CRSP on Friday reported its fourth-quarter and full-year 2025 financial results, highlighting ...
Producing high levels of valuable medicinal compounds in plants has long been limited by the difficulty of precisely ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results